Gilead Sciences (GILD) Other financing activities (2009 - 2026)

Gilead Sciences (GILD) has reported Other financing activities for 18 consecutive years, with -$179.0 million the latest figure, recorded in Q1 2026.

• Other financing activities for Q1 2026 came in at -$179.0 million, down 1.7% year-over-year; the trailing twelve-month figure through Mar 2026 was -$443.0 million (down 29.91% YoY), and the FY2025 annual result was -$440.0 million, down 56.58% from the prior year.
• Other financing activities was -$179.0 million for Q1 2026 at Gilead Sciences, down from -$63.0 million in the prior quarter.
• Over five years, Other financing activities peaked at -$14.0 million in Q2 2022 and troughed at -$179.0 million in Q1 2026.
• Average Other financing activities over 5 years is -$79.5 million, with a median of -$64.0 million recorded in 2025.
• Year-over-year, Other financing activities sank 133.33% in 2022 and grew 14.07% in 2024.
• Over 5 years, Other financing activities stood at -$23.0 million in 2022, then sank by 47.83% to -$34.0 million in 2023, then sank by 38.24% to -$47.0 million in 2024, then plunged by 34.04% to -$63.0 million in 2025, then slumped by 184.13% to -$179.0 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were -$179.0 million in Q1 2026, -$63.0 million in Q4 2025, and -$137.0 million in Q3 2025.